Toni Ibrahim

"Misura" project: a retrospective survey on the use of 5fluorouracil in the treatment of colorectal cancer in 24 Italian clinical centers.

Docetaxel followed by gemcitabine in the treatment of advanced non-small cell lung cancer: a phase I study.

Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients.

Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer.

Innovative sequence of docetaxel-gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: a phase I study.

Improved analysis of 5-Fluorouracil and 5,6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling.

Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study.

Multidisciplinary approach to the treatment of bone metastases: Osteo-Oncology Center, a new organizational model.

A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer.

Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting.

Pathogenesis of osteoblastic bone metastases from prostate cancer.

Time-dependent pharmacokinetics of 5-fluorouracil and association with treatment tolerability in the adjuvant setting of colorectal cancer.

Bone metastases detection by circulating biomarkers: OPG and RANK-L.

The role of CXCR4 in the prediction of bone metastases from breast cancer: a pilot study.

Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients.

Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization.

Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2.

Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid.

Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.

Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors.

miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis.

Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines.

Metastatic bone disease in the era of bone-targeted therapy: clinical impact.

Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial.

RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study.

What can we learn from the ZOOM trial?--Authors' reply.

Bone and cancer: the osteoncology.

Tumor-Induced Osteoclast miRNA Changes as Regulators and Biomarkers of Osteolytic Bone Metastasis.

A new emergency in oncology: Bone metastases in breast cancer patients (Review).

Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey.

Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey.

Targeting bone metastatic cancer: Role of the mTOR pathway.

CSF-1 blockade impairs breast cancer osteoclastogenic potential in co-culture systems.

The microRNA-23b/27b/24 cluster promotes breast cancer lung metastasis by targeting metastasis-suppressive gene prosaposin.

Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey.

ΔNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling.

Single bone metastasis from adenocarcinoma of the lacrimal gland: a case report.

Metronomic capecitabine in gastroenteropancreatic neuroendrocrine tumors: a suitable regimen and review of the literature.

Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib: case report.

Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?

Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer.

Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence.

Hypocalcaemia in patients with metastatic bone disease treated with denosumab.

Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC.

Treatment of cancer patients in their last month of life: aimless chemotherapy.

Paraneoplastic hypocalcemia-induced heart failure in advanced breast cancer: A case report and literature review.

First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma.

Natural History of Non-Small-Cell Lung Cancer with Bone Metastases.

Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: a case report.

Distribution and correlates of non-high-density lipoprotein cholesterol and triglycerides in Lebanese school children.

Corrigendum: Natural History of Non-Small-Cell Lung Cancer with Bone Metastases.

Tirofiban-Induced Thrombocytopenia Occurring with Crohn's Disease.

Characteristics of Incident Testicular Cancer in Lebanon - 1990-2015 Single Institutional Experience.

Development of a Patient-Derived Xenograft (PDX) of Breast Cancer Bone Metastasis in a Zebrafish Model.

Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR).

[Corrigendum] Cisplatin in combination with zoledronic acid: A synergistic effect in triple-negative breast cancer cell lines.

RANKL: A promising circulating marker for bone metastasis response.

Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas.

The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts.

Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model.

Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer.

Activity of Eribulin in a Primary Culture of Well-Differentiated/Dedifferentiated Adipocytic Sarcoma.

The role of 68Ga-DOTA-NOC PET/CT in evaluating neuroendocrine tumors: real-world experience from two large neuroendocrine tumor centers.

Outcome Analysis of First-line Somatostatin Analog Treatment in Metastatic Pulmonary Neuroendocrine Tumors and Prognostic Significance of (18)FDG-PET/CT.

Vitamin D receptor polymorphisms or serum levels as key drivers of breast cancer development? The question of the vitamin D pathway.

Everolimus in Pancreatic Neuroendocrine Carcinomas G3.

PET/CT Scanner and Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Diffuse Large B-Cell Lymphoma.

CORRECTION: Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model.

Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas.

Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors.

Tumor-Stroma Crosstalk in Bone Tissue: The Osteoclastogenic Potential of a Breast Cancer Cell Line in a Co-Culture System and the Role of EGFR Inhibition.

Epidemiology and Survival Analysis of Gastrointestinal Stromal Tumors in Lebanon: Real-life study from a Hospital tumor registry 2000-2015.

Management and potentialities of primary cancer cultures in preclinical and translational studies.

Primary leiomyosarcoma of the bone: a case report and a review of the literature.

Osteoblastic bone metastases from neuroendocrine tumor (NET) of unknown origin detected by 18fluorocholine PET/CT and its comparison with 68gallium-DOTATOC PET/CT: Case report and review of the literature.

Primary Culture of Undifferentiated Pleomorphic Sarcoma: Molecular Characterization and Response to Anticancer Agents.

Myxofibrosarcoma primary cultures: molecular and pharmacological profile.